Walleye Capital’s United Therapeutics UTHR Stock Holding History

Walleye Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$593K	Buy	1,000 +600	+150%	+$299K	﹤0.01%	2520
2025 Q4	$195K	Buy	+400	New	+$186K	﹤0.01%	3555
2025 Q1	–	Sell	-900	Closed	-$318K	–	5168
2024 Q4	$318K	Sell	900 -3,800	-81%	-$1.4M	﹤0.01%	3375
2024 Q3	$1.68M	Buy	4,700 +4,200	+840%	+$1.42M	﹤0.01%	2126
2024 Q2	$159K	Sell	500 -1,300	-72%	-$344K	﹤0.01%	4455
2024 Q1	$413K	Sell	1,800 -700	-28%	-$158K	﹤0.01%	3367
2023 Q4	$550K	Buy	2,500 +1,200	+92%	+$277K	﹤0.01%	2865
2023 Q3	$294K	Buy	1,300 +700	+117%	+$161K	﹤0.01%	3252
2023 Q2	$132K	Buy	+600	New	+$133K	﹤0.01%	3318
2023 Q1	–	Sell	-400	Closed	-$111K	–	4393
2022 Q4	$111K	Buy	+400	New	+$101K	﹤0.01%	2324
2020 Q1	–	Sell	-17,700	Closed	-$1.56M	–	1695
2019 Q4	$1.56M	Sell	17,700 -2,300	-12%	-$202K	0.1%	274
2019 Q3	$1.59M	Sell	20,000 -900	-4%	-$72.5K	0.1%	282
2019 Q2	$1.63M	Buy	20,900 +17,300	+481%	+$1.62M	0.18%	144
2019 Q1	$423K	Buy	+3,600	New	+$419K	0.07%	447

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Walleye Capital's UTHR Position: Q1 2026 in Review

Walleye Capital reduced its United Therapeutics (UTHR) stake by 79% in Q1 2026, selling an estimated $3.94M and leaving 2,166 shares worth $1.28M. The position accounts for 0.01% of the portfolio, ranked #1854.

Walleye Capital first reported a position in UTHR in Q1 2019 and has held it in 20 quarters since. The position peaked at $13M in Q3 2022. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Walleye Capital held 2,166 shares of United Therapeutics worth $1.28M as of Q1 2026.
Walleye Capital sold 7,919 United Therapeutics shares in Q1 2026, an estimated $3.94M.
United Therapeutics made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1854 holding.
Walleye Capital first reported a position in United Therapeutics in Q1 2019 and has held it in 20 quarters since.
Walleye Capital's United Therapeutics position peaked at $13M in Q3 2022.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.